Change to starting dose for Abilify

The Summary of Product Characteristics for the antipsychotic Abilify (aripiprazole) has been revised to include a new starting dose and new safety information

The recommended starting dose for Abilify (aripiprazole) in the treatment of schizophrenia has been changed to 10 mg or 15 mg once daily, with a maintenance dose of 15 mg once daily. Previously, the recommended starting dose was 15mg once daily.

Enhanced efficacy at doses higher than 15 mg once daily has not been demonstrated but some patients may benefit from higher doses of up to 30 mg once daily.

The Summary of Product Characteristics for Abilify has also been amended to warn doctors treating elderly patients with psychosis associated with Alzheimer's dementia that such patients have an increased risk of mortality.

This change follows the results of clinical trials showing a death rate of 3.5% in elderly patients with psychosis treated with aripiprazole compared with a death rate of 1.7% in placebo-treated patients.

Further information: Otsuka
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...